Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-02-21

Clinical Trial Update: Lorlatinib Renal Impairment Study [Phase 1]

View source ↗

Summary

Phase 1 trial update examining lorlatinib in patients with renal impairment; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • lorlatinib (lorlatinib)

Snippet

Sponsor: Pfizer | Conditions: Renal Impairment | Phase 1 | Status: COMPLETED | Results posted: 2021-02-21